Candriam S.C.A. Spectrum Pharmaceuticals Inc Transaction History

Candriam S.C.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 23, 2020	SELL	$2.11 - $3.38 $2.09 Million - $3.35 Million	-990,882 Closed	0 $0
Q4 2019 Jan 21, 2020	SELL	$3.5 - $10.35 $92,813 - $274,461	-26,518 Reduced 2.61%	990,882 $4,000
Q3 2019 Oct 21, 2019	SELL	$7.03 - $9.7 $351,500 - $484,999	-50,000 Reduced 4.68%	1,017,400 $8,000
Q2 2019 Aug 01, 2019	BUY	$7.36 - $11.26 $165,600 - $253,350	22,500 Added 2.15%	1,067,400 $9.15 Million
Q1 2019 May 02, 2019	BUY	$9.08 - $11.84 $590,881 - $770,488	65,075 Added 6.64%	1,044,900 $11.2 Million
Q4 2018 Feb 14, 2019	BUY	$6.39 - $16.99 $1.99 Million - $5.28 Million	310,725 Added 46.44%	979,825 $8.57 Million
Q3 2018 Nov 07, 2018	BUY	$16.52 - $24.82 $6.19 Million - $9.3 Million	374,600 Added 127.2%	669,100 $11.2 Million
Q2 2018 Aug 14, 2018	BUY	$14.31 - $21.75 $1.57 Million - $2.38 Million	109,500 Added 59.19%	294,500 $6.17 Million
Q1 2018 May 09, 2018	BUY	$16.09 - $23.07 $450,520 - $645,960	28,000 Added 17.83%	185,000 $2.98 Million
Q4 2017 Feb 07, 2018	BUY	$13.36 - $20.73 $2.1 Million - $3.25 Million	157,000	157,000 $2.98 Million

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.